Literature DB >> 20890221

Peripheral and intestinal CD4+ T cells with a regulatory phenotype in pediatric patients with inflammatory bowel disease.

Raffaella La Scaleia1, Stefania Morrone, Antonella Stoppacciaro, Stefania Scarpino, Manila Antonelli, Elettra Bianchi, Giovanni Di Nardo, Salvatore Oliva, Franca Viola, Salvatore Cucchiara, Angela Santoni, Gabriella Palmieri, Stefania Uccini.   

Abstract

OBJECTIVES: Regulatory T cells (TR cells) play a crucial role in the regulation of intestinal inflammation. To examine the pathogenetic relevance of TR cells in inflammatory bowel disease (IBD), we evaluated their frequency in peripheral blood and inflamed and noninflamed mucosae of pediatric patients with IBD and age-matched controls without IBD; we also characterized the immune profile of the inflammatory infiltrate in the different phases of the disease. PATIENTS AND METHODS: Circulating TR cells were investigated on peripheral blood mononuclear cells by fluorescence-activated cell sorting analysis; mucosal TR cells and inflammatory cell populations were investigated by immunohistochemistry on bioptic specimens. FOXP3 messenger RNA expression levels were confirmed using real-time polymerase chain reaction.
RESULTS: FOXP3+ TR cells were significantly increased in the intestinal lesions of patients with active IBD, and returned to normal levels in posttherapy remission phase. At variance, circulating TR cell frequency was elevated in patients with IBD independently of disease activity, as it persisted in the remission phase. A selective imbalance in the frequency of CD4+ T and natural killer cell subsets characterized the abundant inflammatory infiltrate of active intestinal lesions, and also persisted, at a lower level, in noninflamed mucosae of patients in the remission phase.
CONCLUSIONS: TR cell frequency is differently regulated in mucosal tissues and at the systemic level during the distinct phases of pediatric IBD. The inactive stage of pediatric IBD is characterized by an incomplete normalization of the immune profile, independently of the clinical efficacy of the therapy. The pediatric, early-onset condition may represent a privileged observatory to dissect the immune-mediated pathogenetic mechanisms at the basis of the disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20890221     DOI: 10.1097/MPG.0b013e3181e4d323

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  5 in total

1.  Lys63-polyubiquitination by the E3 ligase casitas B-lineage lymphoma-b (Cbl-b) modulates peripheral regulatory T cell tolerance in patients with systemic lupus erythematosus.

Authors:  J Romo-Tena; S Rajme-López; L Aparicio-Vera; J Alcocer-Varela; D Gómez-Martín
Journal:  Clin Exp Immunol       Date:  2017-10-19       Impact factor: 4.330

2.  Distinct kinetics in the frequency of peripheral CD4+ T cells in patients with ulcerative colitis experiencing a flare during treatment with mesalazine or with a herbal preparation of myrrh, chamomile, and coffee charcoal.

Authors:  Jost Langhorst; Annika Frede; Markus Knott; Eva Pastille; Jan Buer; Gustav J Dobos; Astrid M Westendorf
Journal:  PLoS One       Date:  2014-08-21       Impact factor: 3.240

Review 3.  Opportunities to Target T Cell Trafficking in Pediatric Inflammatory Bowel Disease.

Authors:  Eirini Giannoudaki; Siobhan Gargan; Seamus Hussey; Aideen Long; Patrick T Walsh
Journal:  Front Pediatr       Date:  2021-03-18       Impact factor: 3.418

4.  Expression of TIM-3, Human β-defensin-2, and FOXP3 and Correlation with Disease Activity in Pediatric Crohn's Disease with Infliximab Therapy.

Authors:  Mi Jin Kim; Woo Yong Lee; Yon Ho Choe
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

Review 5.  Dissecting the Heterogeneity in T-Cell Mediated Inflammation in IBD.

Authors:  Irma Tindemans; Maria E Joosse; Janneke N Samsom
Journal:  Cells       Date:  2020-01-02       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.